Related references
Note: Only part of the references are listed.Peak Concentrations of Ustekinumab After Intravenous Induction Therapy Identify Patients With Crohn's Disease Likely to Achieve Endoscopic and Biochemical Remission
Jurij Hanzel et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2021)
Biomarkers of Inflammation in Inflammatory Bowel Disease: How Long before Abandoning Single-Marker Approaches?
Gabriele Dragoni et al.
DIGESTIVE DISEASES (2021)
S902 Intestinal Ultrasound Response and Transmural Remission After 48 Weeks of Treatment With Ustekinumab in Crohn’s Disease: STARDUST Trial Substudy Results by Line of Treatment and by Location
Torsten Kucharzik et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2021)
Development and Validation of an Interleukin-6 Nomogram to Predict Primary Non-response to Infliximab in Crohn's Disease Patients
Yueying Chen et al.
FRONTIERS IN PHARMACOLOGY (2021)
Interrogating host immunity to predict treatment response in inflammatory bowel disease
Jonathan L. Digby-Bell et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2020)
Monitoring vedolizumab and ustekinumab drug levels in patients with inflammatory bowel disease: hype or hope?
Dahham Alsoud et al.
CURRENT OPINION IN PHARMACOLOGY (2020)
Ustekinumab Exposure-outcome Analysis in Crohn's Disease Only in Part Explains Limited Endoscopic Remission Rates
Bram Verstockt et al.
JOURNAL OF CROHNS & COLITIS (2019)
IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting
Alexander R. Moschen et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2019)
A Combined Set of Four Serum Inflammatory Biomarkers Reliably Predicts Endoscopic Disease Activity in Inflammatory Bowel Disease
Arno R. Bourgonje et al.
FRONTIERS IN MEDICINE (2019)
Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease
Omoniyi J. Adedokun et al.
GASTROENTEROLOGY (2018)
Immunological pathogenesis of inflammatory bowel disease
Seung Hoon Lee et al.
INTESTINAL RESEARCH (2018)
Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn's Disease: A Phase 2a Study
Bruce E. Sands et al.
GASTROENTEROLOGY (2017)
Serum Amyloid A as a Surrogate Marker for Mucosal and Histologic Inflammation in Patients with Crohn's Disease
Andres J. Yarur et al.
INFLAMMATORY BOWEL DISEASES (2017)
Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease
B. G. Feagan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Role of endoscopy, cross-sectional imaging and biomarkers in Crohn's disease monitoring
Jose-Manuel Benitez et al.
GUT (2013)
The Utility of Biomarkers in the Diagnosis and Therapy of Inflammatory Bowel Disease
James D. Lewis
GASTROENTEROLOGY (2011)
Serum Lipopolysaccharide-binding Protein and Soluble CD14 Are Markers of Disease Activity in Patients with Crohn's Disease
Peter Laszlo Lakatos et al.
INFLAMMATORY BOWEL DISEASES (2011)
The increased expression of IL-23 in inflammatory bowel disease promotes intraepithelial and lamina propria lymphocyte inflammatory responses and cytotoxicity
Zhanju Liu et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2011)
Oratory markers in IBD: Magic, or unneccessary toys?
S Vermeire et al.
GUT (2006)
Share Paper
